EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

The impact of the United States most favored nation policies on prices of branded medicines and research and development

David Epstein

Health Policy OPEN · 2026-11 · 11 · 100180

DOI: 10.1016/j.hpopen.2026.100180 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Health Policy OPEN, 2026-11. Verfasst von David Epstein. Beteiligte Einrichtung: Department of Applied Economics, University of Granada, Campus de Cartuja, s/n, 18071 Granada, Spain. Die Arbeit nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The Executive Order (EO) reintroducing the Most Favored Nation (MFN) policy sets out measures to lower prices of branded medicines in the United States (US) and increase them elsewhere.

Methods

To understand the impact of the policy on prices and on pharmaceutical innovation, this paper reviews empirical literature on historic price trends in the US and other high-income countries, the impact of international reference pricing (IRP), and the impact of regulation and market conditions on Research and Development (R&D).

Results

49 studies were included. List prices are greater in the US than other high-income countries, and the difference in net prices has widened in the last two decades. The IRP literature indicates that for some drugs, MFN might be able to reduce prices in the US and increase them in reference countries, particularly for drugs where Medicare and Medicaid have a high global market share. In other cases, firms may strategically delay or cancel launch in other countries to avoid price comparisons. It is likely that MFN will provoke a reduction in global pharma revenues and aggregate investment in R&D.

Conclusion

A few countries are increasing prices as part of trade deals with the US. If countries do not wish to increase prices, then they should expect, and prepare for, slower pharma innovation. From a public health perspective, it is not just aggregate R&D that matters, but whether R&D investment is directed to projects which are likely to promote the greatest health gain.

Schlagwörter

Stichwörter der Autor:innen

DrugsInternational reference pricingMost Favored nationPharmaceuticalsResearch and Development

Autor:innen und Institutionen

  • Department of Applied Economics, University of Granada, Campus de Cartuja, s/n, 18071 Granada, Spain.

Zitieren

APA

Epstein, D. (2026). The impact of the United States most favored nation policies on prices of branded medicines and research and development. Health Policy OPEN, 11, 100180. https://doi.org/10.1016/j.hpopen.2026.100180

Vancouver

Epstein D. The impact of the United States most favored nation policies on prices of branded medicines and research and development. Health Policy OPEN. 2026;11:100180. doi:10.1016/j.hpopen.2026.100180

BibTeX
@article{Epstein2026,
  author = {Epstein, David},
  title = {The impact of the United States most favored nation policies on prices of branded medicines and research and development},
  journal = {Health Policy OPEN},
  year = {2026},
  volume = {11},
  pages = {100180},
  doi = {10.1016/j.hpopen.2026.100180}
}
Kostenlos starten →